MediciNova, Inc. (NASDAQ:MNOV - Free Report) - Investment analysts at HC Wainwright boosted their FY2026 earnings per share estimates for shares of MediciNova in a research note issued on Monday, November 16th. HC Wainwright analyst L. Egana-Gorrono now expects that the biopharmaceutical company will post earnings of ($0.21) per share for the year, up from their previous forecast of ($0.28). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for MediciNova's current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for MediciNova's Q4 2026 earnings at ($0.06) EPS, FY2027 earnings at ($0.35) EPS, FY2028 earnings at $0.39 EPS, FY2029 earnings at $2.02 EPS and FY2030 earnings at $3.15 EPS.
Several other research firms also recently commented on MNOV. Weiss Ratings raised shares of MediciNova from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, September 2nd. Roth Capital began coverage on shares of MediciNova in a report on Thursday, September 17th. They set a "buy" rating and a $6.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, MediciNova currently has an average rating of "Moderate Buy" and a consensus price target of $7.75.
Read Our Latest Report on MNOV
MediciNova Price Performance
NASDAQ MNOV opened at $1.34 on Wednesday. The stock has a market capitalization of $68.65 million, a PE ratio of -6.38 and a beta of 0.71. The company has a 50 day moving average price of $1.77 and a two-hundred day moving average price of $1.50. MediciNova has a 12-month low of $1.22 and a 12-month high of $3.90.
MediciNova (NASDAQ:MNOV - Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting analysts' consensus estimates of ($0.06). The firm had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.05 million. MediciNova had a negative return on equity of 26.47% and a negative net margin of 1,126.60%.
Insider Buying and Selling at MediciNova
In other news, major shareholder 3D Investment Partners Pte. Lt sold 640,000 shares of the company's stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $2.70, for a total transaction of $1,728,000.00. Following the completion of the sale, the insider owned 4,862,047 shares in the company, valued at approximately $13,127,526.90. This represents a 11.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 14.00% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Jump Financial LLC acquired a new stake in MediciNova in the 3rd quarter worth approximately $30,000. Empowered Funds LLC bought a new stake in MediciNova during the third quarter worth approximately $83,000. Bank of New York Mellon Corp bought a new stake in MediciNova during the second quarter worth approximately $103,000. Finally, Goldman Sachs Group Inc. acquired a new position in MediciNova during the third quarter valued at approximately $1,032,000. Institutional investors and hedge funds own 9.90% of the company's stock.
About MediciNova
(
Get Free Report)
MediciNova is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries. Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MediciNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.
While MediciNova currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.